Actively Recruiting
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Led by Peking Union Medical College Hospital · Updated on 2025-09-05
18
Participants Needed
2
Research Sites
318 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Due to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can improve the R0 resection rate with preservation of adjacent organs in T4 colon cancer patients with dMMR.
CONDITIONS
Official Title
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-75 years
- ECOG performance status score between 0 and 2
- Adenocarcinoma confirmed by pathology and dMMR confirmed by immunohistochemistry or PCR
- Tumor located in the cecum, ascending colon, transverse colon, or sigmoid colon
- Clinical stage cT4 with loss of space between tumor and adjacent organs or invasion of adjacent organs as shown by enhanced CT
- R0 resection not achievable according to intraoperative exploration
- No evidence of distant metastasis
- Newly diagnosed patients who have not received chemotherapy or surgery
- Adequate liver, kidney, and other organ function to tolerate treatment
- Ability to understand the study and provide informed consent
You will not qualify if you...
- History of other malignant tumors within the past 5 years (except cured basal cell carcinoma, cervical carcinoma in situ, treated localized prostate cancer, or resected breast ductal carcinoma in situ)
- Complicated intestinal obstruction, perforation, gastrointestinal bleeding, or other conditions requiring emergency surgery
- Pregnant or breastfeeding women
- History of severe mental illness, immune diseases, or hormone medication use
- Contraindications to immunotherapy or surgery
- Participation in other clinical studies within the past 3 months
- Any other condition deemed inappropriate for inclusion by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
2
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
Z
Zhen Sun, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here